April 19, 2016
Sosei Group announced on April 18 that its wholly owned UK subsidiary Heptares Therapeutics and Kymab, a human monoclonal antibody biopharmaceutical company, have entered into a collaboration deal to discover, develop, and commercialize novel antibody drugs targeting a range of...read more